We would like to thank Dr Gupta for taking an interest in our recent publication and welcome his comments because they emphasize the arbitrary nature of what is meant by "long-term" and "midterm." Although our series was first presented in abstract form at the this opportunity to respectfully acknowledge those authors. Nevertheless, the real issue, which we consider to be debatable, is what is meant by "long-term follow-up" and "midterm follow-up." In the discussion section of our recent paper, we indicated that we were reporting "late midterm follow-up" (mean, 31 months) for our cohort, not "long-term" follow-up 2 We used this expression specifically because in patients with symptomatic intracranial atherosclerosis, we consider "long-term" follow-up to be approximately 4 years. We believe that in clinical research, the definition of "long-term" follow-up is not only highly subjective but also highly dependent on the pathology, treatment, and patient population. We are not aware of any regulatory document or clinical research manual that provides a standardized definition of "long-term" and "midterm" as they apply to follow-up in clinical research. Although some clinical series have reported a median follow-up of 6.5 years as "midterm,"
3 others have reported a mean follow-up of 10 months as "midterm." 4 Because these definitions are somewhat arbitrary, we could set the threshold for "late midterm" at 30 months. Using this cutoff, our series would be the first to report a cohort of patients with "late midterm" follow-up after stent placement of symptomatic basilar artery stenosis. 2 In patients with symptomatic intracranial atherosclerosis, we think that the WASID study properly defines what should be considered "long-term." 5 In a subgroup analysis of the WASID study data, curves that plot the cumulative risk of ischemic stroke in the territory of the index stenosis against the follow-up period plateau between 3 and 4 years. 6 Consequently, therapies for this condition are primarily aimed at preventing events that occur within a 3-to 4-year window. This would effectively define the threshold for "long-term" follow-up of this condition to be 4 years. Because Yu et al 1 have reported a series of patients with a mean follow-up of 26.7 months, they have not met our standard of "long-term" follow-up, as indicated in the title of the publication, and as claimed by Dr Gupta. If we define 4 years as "longterm" follow-up, then 2 years could reasonably be considered "midterm." Extension of this logic suggests that 2 to 4 years would be classified as "late midterm" follow-up. The mean follow-up in our series was 31 months, consistent with the designation "late midterm" follow-up as we have published.
